Key Highlights

  • City Therapeutics (NASDAQ:CTY) rose about 28% in its Nasdaq debut on Friday, October 16, 2026, after pricing 11,111,111 shares at USD 18.00, the middle of a USD 17 to USD 19 range.
  • The RNA interference developer upsized the deal from about 9.7 million shares, raising gross proceeds of about USD 200 million, with Goldman Sachs, Jefferies, Stifel and Oppenheimer as bookrunners.
  • Reports put the raise at USD 200 million and about USD 230 million. The higher figure matches the deal with the 1,666,666-share underwriter option exercised in full, simple arithmetic on the published terms.
  • Three days later Merck KGaA agreed to buy Silence Therapeutics (NASDAQ:SLN), another RNA interference developer, for about USD 1.3 billion, a sector read-across rather than a link between the two companies.

How the Offering Was Priced

City Therapeutics (NASDAQ:CTY) began trading on the Nasdaq Global Market on Friday, October 16, 2026. It rose about 28% in its debut, according to Yahoo Finance. The company priced 11,111,111 shares at USD 18.00, in the middle of its USD 17 to USD 19 range, after increasing the share count from about 9.7 million. Gross proceeds were about USD 200 million before fees. Underwriters received a 30-day option to buy up to 1,666,666 more shares, and closing was expected on Monday, October 19. A 28% gain on USD 18.00 implies a level near USD 23, simple arithmetic on the offer price, as the exact first-day close was not captured. Renaissance Capital said City and Iambic headlined the week.

Why an Upsized Deal Can Still Pop

An upsized deal priced at the midpoint usually signals that the order book held more demand than the shares offered. Bankers sometimes leave the price unchanged and sell more shares, accepting a first-day gain in exchange for a broader shareholder base. City Therapeutics (NASDAQ:CTY) develops RNA interference medicines, which silence a disease-causing gene by destroying its messenger RNA before a protein is made. Investors in the field received a valuation marker on Monday, October 19, when Merck KGaA agreed to pay USD 20 per American depositary share for Silence Therapeutics, an equity value of about USD 1.3 billion. That deal is a read-across for the platform, not evidence about City's own pipeline or prospects.

Risks and What to Watch

The first risk is that a first-day gain fades. Early trading is thin, and gains can reverse once the offering closes and the stabilisation period ends. The second risk is clinical: City Therapeutics (NASDAQ:CTY) is valued on future medicines, so trial delays or safety findings can move the shares sharply. The third risk is the market backdrop, with a 10-year Treasury yield near 5.11% raising the discount rate applied to long-dated biotech cash flows. A lock-up, the period in which insiders cannot sell, will end at a later date that was not captured. Investors should watch whether the underwriter option is exercised, the first quarterly report and the Fed decision on Wednesday, October 28.

Where Things Stand

The answer is that City Therapeutics (NASDAQ:CTY) drew enough demand to upsize its offering and still trade about 28% above the USD 18.00 price. That points to appetite for RNA interference platforms, reinforced by the Silence Therapeutics bid three days later. Gains made on a first day are not a guide to clinical results. The next catalysts are the underwriter option, the Fed meeting on October 27 to 28 and the company's first earnings report as a public company. Early trading levels are not guarantees, and this is not investment advice.